

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
14875-151US1Application No.  
10/550,934
**Information Disclosure Statement  
by Applicant**  
 (Use several sheets if necessary)

(37 CFR 1.98(b))

Applicant  
Masayuki Tsuchiya et al.Filing Date  
August 25, 2006Group Art Unit  
1645**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/AMG/	AA	5,877,291	04/20/1995	Mezes et al.			
	AB	6,323,000	11/07/2001	Briggs et al.			
	AC	6,342,220	01/29/2002	Adams et al.			
	AD	6,683,157	01/27/2004	Briggs et al.			
	AE	2001/0006796	07/05/2001	Briggs et al.			
	AF	2002/0193571	12/19/2002	Carter et al.			
	AG	2003/0073161	04/17/2003	Briggs et al.			
	AH	2004/0091475	05/13/2004	Tsuchiya et al.			
	AI	2004/0242847	12/02/2004	Fukushima et al.			
	AJ	2006/0189794	08/24/2006	Tsuchiya et al.			
↓	AK	2006/0222643	10/05/2006	Tsunoda et al.			
/AMG/	AL	2006/0275301	12/07/2006	Ozaki et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/AMG/	AM	JP 7-503622	04/20/1995	Japan			See AA	
	AN	JP 2001/506135	05/15/2001	Japan			See AE	
	AO	JP 2001/513999	09/11/2001	Japan			See AC	
	AP	WO 97/31108	08/28/1997	WIPO			English abstract	
	AQ	WO 98/28331	07/02/1998	WIPO				
	AR	WO 98/41641	09/24/1998	WIPO				
	AS	WO 99/02567	01/21/1999	WIPO				
	AT	WO 99/10494	03/04/1999	WIPO				
	AU	WO 01/64713	09/07/2001	WIPO				
↓	AV	WO 01/66737	09/13/2001	WIPO			English abstract	
↓	AW	WO 01/79494	10/25/2001	WIPO			English abstract	
/AMG/	AX	WO 02/33072	04/25/2002	WIPO			See AG	

Examiner Signature /Anne M. Gussow/ Date Considered 05/28/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 14875-151US1	Application No. 10/550,934	
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.				
(37 CFR §1.98(b))		Filing Date August 25, 2006		Group Art Unit 1645		

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/AMG/	AY	WO 02/33073	04/25/2002	WIPO			See AH	
/AMG/	AZ	WO 2004/033499	04/22/2004	WIPO			X	
/AMG/	AAA	WO 2004/081048	09/23/2004	WIPO			X	

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/AMG/	ABB	Ballmaier et al., "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia," <i>Blood</i> , 97:139-146 (2001)
	ACC	Brinkmann et al., "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity," <i>Curr. Opin. Immunol.</i> , 14:569-575 (2002)
	ADD	Bruenke et al., "A recombinant bispecific single-chain Fv antibody against HLA class II and Fc $\gamma$ RIII (CD16) triggers effective lysis of lymphoma cells," <i>Br. J. Haematol.</i> , 125:167-179 (2004)
	AEE	Clark, "CD22, a B Cell-Specific Receptor, Mediates Adhesion and Signal Transduction," <i>J. Immunol.</i> , 150:4715-4718 (1993)
	AFF	Co et al., "A Humanized Antibody Specific for the Platelet Integrin gpIIb/IIIa," <i>J. Immunol.</i> , 152:2968-2976 (1994)
	AGG	Daniel et al., "Induction of Apoptosis in Human Lymphocytes by Human Anti-HLA Class I Antibodies," <i>Transplantation</i> , 75:1380-1386 (2003)
	AHH	De Felice et al., "Differential regulatory role of monomorphic and polymorphic determinants of histocompatibility leukocyte antigen class I antigens in monoclonal antibody OKT3-induced T cell proliferation," <i>J. Immunol.</i> , 139:2683-2689 (1987)
	AII	DeNardo et al., "Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy," <i>Cancer Biother. Radiopharm.</i> , 16:525-535 (2001)
	AJJ	Deng et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryopoiesis," <i>Blood</i> , 92:1981-1988 (1998)
	AKK	Ebert et al., "Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric Cancer," <i>Cancer Res.</i> , 60:1995-2001 (2000)
	ALL	Elliott et al., "Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies," <i>J. Biol. Chem.</i> , 271:24691-24697 (1996)
	AMM	Genestier et al., "Antibodies to HLA Class 1 $\alpha 1$ Domain Trigger Apoptosis of CD40-Activated Human B Lymphocytes," <i>Blood</i> , 90:726-735 (1997)
	ANN	Genestier et al., "Caspase-dependent Ceramide Production in Fas- and HLA Class I-mediated Peripheral T Cell Apoptosis," <i>J. Biol. Chem.</i> , 273:5060-5066 (1998)
↓	AOO	Genestier et al., "T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2 and interleukin-4," <i>Eur. J. Immunol.</i> , 27:495-499 (1997)
/AMG/	APP	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 94:7509-7514 (1997)

Examiner Signature	/Anne M. Gussow/	Date Considered	05/28/2008
--------------------	------------------	-----------------	------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-151US1	Application No. 10/550,934
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masayuki Tsuchiya et al.		
		Filing Date August 25, 2006	Group Art Unit 1645	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/AMG/	AQQ	Goel et al., "99mTc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma," <i>J. Nucl. Med.</i> , 42:1519-1527 (2001)	
	ARR	Goel et al., "Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application," <i>Cancer Res.</i> , 60:6964-6971 (2000)	
	ASS	Goto et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells," <i>Blood</i> , 84:1922-1930 (1994)	
	ATT	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," <i>J. Immunol. Methods</i> , 231:177-189 (1999)	
	AUU	Kimura et al., "2D7 diabody bound to the $\alpha 2$ domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells," <i>Biochem. Biophys. Res. Commun.</i> , 325:1201-1209 (2004)	
	AVV	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," <i>J. Mol. Biol.</i> , 330:99-111 (2003)	
	AWW	Kortt et al., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting," <i>Biomol. Eng.</i> , 18:95-108 (2001)	
	AXX	Kulkarni et al., "Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility Complex," <i>Transplant. Proc.</i> , 30:1081 (1998)	
	AYY	Kulkarni et al., "Programmed Cell Death Signaling Via Cell-Surface Expression of a Single-Chain Antibody Transgene," <i>Transplantation</i> , 69:1209-1217 (2000)	
	AZZ	Lebrun et al., "Antibodies to the Extracellular Receptor Domain Restore the Hormone-insensitive Kinase and Conformation of the Mutant Insulin Receptor Valine 382," <i>J. Biol. Chem.</i> , 268:11272-11277 (1993)	
	AAAA	Li et al., "The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies," <i>Cell. Immunol.</i> , 118:85-99 (1989)	
	ABBB	Matsuoka et al., "A Monoclonal Antibody to the $\alpha 2$ Domain of Murine Major Histocompatibility Complex Class I that Specifically Kills Activated Lymphocytes and Blocks Liver Damage in the Concanavalin A Hepatitis Model," <i>J. Exp. Med.</i> , 198:497-503 (2003)	
	ACCC	Nishii, "CD22 antibody therapy," <i>Current Therapy</i> , 20:47-50 (2001) (English translation included)	
	ADDD	Oka, "Development of Novel Immunotoxin Using Recombinant Alpha-Sarcin and Its Application Treatment of Hematopoietic Tumor," <i>Sankyo Seimeい Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu</i> , 12:46-56 (1998) (concise English explanation included)	
	AEEE	Orita et al., "A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor," <i>Blood</i> , 105:562-566 (2005)	
	AFFF	Ozaki et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, Abstract No. 3474 (2003)	
↓	AGGG	Ozaki et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24," <i>Blood</i> , 90:3179-3186 (1997)	
/AMG/	AHHH	Pettersen et al., "The TCR-Binding Region of the HLA Class I $\alpha 2$ Domain Signals Rapid Fas-Independent Cell Death: A Direct Pathway for T Cell-Mediated Killing of Target Cells?" <i>J. Immunol.</i> , 160:4343-4352 (1998)	

Examiner Signature	/Anne M. Gussow/	Date Considered	05/28/2008
--------------------	------------------	-----------------	------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-151US1	Application No. 10/550,934
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1645

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/AMG/	AIII	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)
	AJJJ	Rossi et al., "Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy," <i>Clin. Cancer Res.</i> , 9:3886s-3896s (2003)
	AKKK	Sato et al., "CD22 Is Both a Positive and Negative Regulator of B Lymphocyte Antigen Receptor Signal Transduction: Altered Signaling in CD22-Deficient Mice," <i>Immunity</i> , 5:551-562 (1996)
	ALLL	Scheurle et al., "Cancer Gene Discovery Using Digital Differential Display," <i>Cancer Res.</i> , 60:4037-4043 (2000)
	AMMM	Smith et al., "Inhibition of T Cell Activation by a Monoclonal Antibody Reactive Against the $\alpha\beta$ Domain of Human MHC Class I Molecules," <i>J. Immunol.</i> , 153:1054-1067 (1994)
	ANNN	Tahitis et al., "Biodistribution Properties of $^{111}\text{In}$ -labeled C-Functionalized <i>trans</i> -Cyclohexyl Diethylenetriaminepentaacetic Acid Humanized 3S193 Diabody and F(ab') <sub>2</sub> Constructs in a Breast Carcinoma Xenograft Model," <i>Clin. Cancer Res.</i> , 7:1061-1072 (2001)
	AOOO	Tedder et al., "CD22, a B Lymphocyte-Specific Adhesion Molecule That Regulates Antigen Receptor Signaling," <i>Annu. Rev. Immunol.</i> , 15:481-504 (1997)
	APPP	Thilenius et al., "Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants," <i>Eur. J. Immunol.</i> , 27:1108-1114 (1997)
	AQQQ	Woodle et al., "Anti-Human Class I $\alpha\beta$ Domain-Specific Monoclonal Antibody Induces Programmed Cell Death in Murine Cells Expressing Human Class I MHC Transgenes," <i>Transplant. Proc.</i> , 30:1059-1060 (1998)
	ARRR	Woodle et al., "Anti-Human Class I MHC Antibodies Induce Apoptosis by a Pathway That Is Distinct from the Fas Antigen-Mediated Pathway," <i>J. Immunol.</i> , 158:2156-2164 (1997)
	ASSS	Woodle et al., "Class I MHC Mediates Programmed Cell Death in Human Lymphoid Cells," <i>Transplantation</i> , 64:140-146 (1997)
	ATTT	Wu et al., "Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers," <i>Immunotechnology</i> , 2:21-36 (1996)
↓	AUUU	Xiong et al., "Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody," <i>Cancer Lett.</i> , 177:29-39 (2002)
/AMG/	AVVV	Xu et al., "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver," <i>Proc. Natl. Acad. Sci. USA</i> , 98:15089-15094 (2001)

Examiner Signature  /Anne M. Gussow/	Date Considered  05/28/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	